- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
South San Francisco Today
By the People, for the People
Aligos Therapeutics Licenses Hepatitis B Drug to Xiamen Amoytop for Greater China
Aligos to receive $25M upfront and up to $420M in milestones plus royalties on sales in the region
Apr. 16, 2026 at 12:49pm
Got story updates? Submit your updates here. ›
A new partnership aims to accelerate the development of a promising hepatitis B drug for the Greater China market.South San Francisco TodayAligos Therapeutics, a clinical-stage biopharmaceutical company, has entered into an exclusive license agreement with Xiamen Amoytop Biotech Co., Ltd. to develop and commercialize its hepatitis B drug pevifoscorvir sodium in Greater China, including Mainland China, Taiwan, Hong Kong, and Macau. Under the terms of the deal, Aligos will receive an upfront payment of $25 million and is eligible for up to $420 million in clinical, regulatory, and sales milestones, as well as tiered, high single-digit royalties on net sales in Amoytop's licensed territories.
Why it matters
This agreement is expected to accelerate the development and commercialization of pevifoscorvir sodium in the Greater China region, which has over 90 million people living with chronic hepatitis B. Amoytop's leadership in the Mainland China hepatology market and robust commercial organization will help drive broader adoption of the drug. The partnership also allows Aligos to focus on pursuing similar strategies for pevifoscorvir sodium in other global markets, including the United States, Europe, Japan, and South Korea.
The details
Pevifoscorvir sodium is a potential first and best-in-class capsid assembly modulator (CAM-E) being developed by Aligos for chronic hepatitis B virus (HBV) infection. It is currently in Phase 2 clinical trials, with the second interim analysis expected in the second half of 2026 and topline data planned for 2027. The drug is designed to improve clinical outcomes by affecting the entire HBV lifecycle, blocking replication, preventing DNA integration, and reducing the cccDNA reservoir.
- The closing of this transaction is conditional and automatically effective upon Amoytop receiving approval at a Shareholders' Meeting, which is anticipated within 30 days.
- The second interim analysis of the Phase 2 B-SUPREME study for pevifoscorvir sodium is expected in the second half of 2026.
- Topline data from the Phase 2 B-SUPREME study for pevifoscorvir sodium is planned for 2027.
The players
Aligos Therapeutics, Inc.
A clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases.
Xiamen Amoytop Biotech Co., Ltd.
An innovative biopharmaceutical company and a listed company on the Science and Technology Innovation Board (SSE STAR Market) in China, specializing in R&D, manufacturing and marketing of regular and long-acting recombinant protein drugs, with a focus on immune-related cytokine medicines.
What they’re saying
“We are pleased to build on our established relationship with Amoytop, a trusted partner through our preclinical antisense oligonucleotide (ASO) program, ALG-170675, for chronic HBV infection.”
— Lawrence Blatt, Chairman, President, and Chief Executive Officer of Aligos Therapeutics
“Aligos is at the forefront of HBV innovation, and we are pleased to deepen our partnership with this outstanding team. We believe pevifoscorvir sodium has the potential to transform chronic HBV suppression, and we are proud to license this important program for Greater China.”
— Sun Li, Chairman and Chief Executive Officer at Amoytop
What’s next
The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.
The takeaway
This deal highlights Aligos' strategy to partner with leading regional players like Amoytop to accelerate the development and commercialization of its innovative hepatitis B therapies in key markets, while allowing the company to focus on other global opportunities for its pipeline.
